Zinc-64 Aspartate

PreclinicalSmall molecule

VVector Vitale LLC

Zinc-64 Aspartate is one of 6 small molecule programs targeting CLL. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CLLRecruiting

CLLPreclinical

Recruiting

Competition

Competitive Landscape

5 competitors in CLL

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

7 2

Rituxan

Roche

Phase 3

5 3

Gazyva

Roche

Phase 3

3 4

Brukinsa

BBeOne Medicines

Phase 3

2 5

Epkinly

Genmab

Phase 2

1 6

Zinc-64 Aspartate

VVector Vitale LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

PreclinicalRecruiting

CLL

NCT06506643

Clinical

Trials by Indication[1]

CLL1 trial

A Phase I/II Open-label Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety and Efficacy of KLS-1 as Monotherapy in Patients With Malignant Neoplasms

Recruiting·VVector Vitale LLC·Preclinical·NCT06506643·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zinc-64 Aspartate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zinc-64 Aspartate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zinc-64 Aspartate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vector Vitale LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVector Vitale LLC

Zinc-64 Aspartate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

CLL1 trial

References

Drug Info

Quick Facts

Related News